The company’s Consumer Health Concerns Study 2021 (which surveyed almost 19,000 consumers across 24 countries) showed 61% of consumers worldwide are now concerned about their gut health
Royal DSM has secured FDA New Dietary Ingredient (NDI) status for its Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri 12246-CU probiotic strains. The health and nutrition company says this development bolsters its capabilities as an end-to-end partner for North American companies in the gut health space.
The company’s Consumer Health Concerns Study 2021 (which surveyed almost 19,000 consumers across 24 countries) showed 61% of consumers worldwide are now concerned about their gut health and 67% of those take action to support it. DSM’s probiotic strains are now available to customers in the US region as market-ready products.
The strains demonstrate multiple clinically-proven gut-related benefits when combined, the company says, including improved digestive comfort and reduced diarrhoea. The accessibility of these strains in the US follows the recent ‘No Objection of NDI submission’ by the FDA. The strains are already commercially available in Europe, Asia and the Middle East.
“Our growing global presence in the gut health market signifies our continued investment in this trending category, where growth is driven by changing consumer mindsets,” said Jill Porter, Global Director Gut Health, Dietary Supplements, DSM.
“The NDI status of our two flagship strains strengthens confidence in our science-based ingredients and creates a multitude of opportunities for our US-based customers to remain at the forefront of the market,” said Penny Antonopoulos, Director Dietary Supplements, Human Nutrition & Care, North America, DSM.
“Both strains were identified as among the best performing probiotic varieties – out of a total of 47 – by a large and comprehensive screening program. Both strains, for example, demonstrated excellent pH tolerance and adhesion properties to enable passage through the gastrointestinal tract and strong antimicrobial activity against pathogenic bacteria. Because of this, the strains were specifically chosen to support customers looking to innovate in the gut health space across a number of applications.”